Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Single Cell Network Profiling (SCNP) of Early-Stage Chronic Lymphocytic Leukemia (CLL): Association with p53, IGHV Mutational Status and Time to First Treatment (TTFT)

Jason Ptacek, PhD, Erik Evensen, Rachael E. Hawtin, Ph.D., Greg Friedland, Jodi R. Ware, PharmD, James Cordeiro, Nadia Peragine, Ph.D, Alessandra Cesano, M.D., Ph.D., Robin Foà, MD, Anna Guarini, PhD

Blood (2012) 120 (21): 1783.

https://doi.org/10.1182/blood.V120.21.1783.1783

Published: 2012

Journal Articles

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Sabina Chiaretti, MD, PhD, Marilisa Marinelli, PhD, Ilaria Del Giudice, MD, PhD, Silvia Bonina, PhD student, Sara Gabrielli, Miss, Alfonso Piciocchi, Monica Messina, PhD, Marco Vignetti, MD, Davide Rossi, MD, PhD, Valeria Di Maio, Miss, Francesca Romana Mauro, MD, Anna Guarini, PhD, Gianluca Gaidano, MD, PhD, Robin Foà, MD

Blood (2012) 120 (21): 1784.

https://doi.org/10.1182/blood.V120.21.1784.1784

Published: 2012

Journal Articles

Targeting Metabolic Pathways for Leukemia Treatment

Simone Mirabilii, Maria Rosaria Ricciardi, Matteo Allegretti, Roberto Licchetta, Stefano Iacovelli, Paola Bergamo, Maria Teresa Petrucci, Raffaella Nicolai, Gianfranco Peluso, Robin Foà, MD, Giuliana Alimena, Agostino Tafuri

Blood (2012) 120 (21): 1371.

https://doi.org/10.1182/blood.V120.21.1371.1371

Published: 2012

Journal Articles

Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia

Blood (2012) 120 (21): 712.

https://doi.org/10.1182/blood.V120.21.712.712

Published: 2012

Journal Articles

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Francesca R Mauro, MD, PhD, Daniele Armiento, MD, Serelina Coluzzi, MD, Maria S De Propris, PhD, Francesca Paoloni, BS, Gianluca Giovannetti, MD, Matteo Molica, MD, Luisa Quattrocchi, MD, Michelina Santopietro, MD, Chiara Spadafora, Lucia Granati, MD, Mara Riminucci, MD, Anna Guarini, PhD, Gabriella Girelli, MD, Robin Foà, MD

Blood (2012) 120 (21): 3192.

https://doi.org/10.1182/blood.V120.21.3192.3192

Published: 2012

Journal Articles

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Francesca R Mauro, MD, PhD, Mara Riminucci, MD, Davide Rossi, MD, PhD, Francesca Paoloni, BS, Luca Laurenti, MD, Anna M Frustaci, MD, Giuseppe Cimino, MD, Michelina Santopietro, MD, Chiara Spadafora, Angela Rago, M.D., Francesco Autore, MD, Molica Matteo, MD, Brocchieri Simonetta, MD, Emanuele Nicolai, MD, Gianluca Gaidano, MD, PhD, Anna Guarini, PhD, Bianco Paolo, MD, Robin Foà, MD

Blood (2012) 120 (21): 3888.

https://doi.org/10.1182/blood.V120.21.3888.3888

Published: 2012

Journal Articles

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Vincenzo Federico, MD, Russo Eleonora, MD, PhD, Andrea Truini, MD, Anna Levi, MD, PhD, Fabiana Gentilini, MD, Giulia Biagioli, Caterina Leoni, MD, Robin Foà, MD, Maria Teresa Petrucci, MD

Blood (2012) 120 (21): 4056.

https://doi.org/10.1182/blood.V120.21.4056.4056

Published: 2012

Journal Articles

Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).

Blood (2012) 120 (21): 2497.

https://doi.org/10.1182/blood.V120.21.2497.2497

Published: 2012

Journal Articles

Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Cristina Papayannidis, Paola Bresciani, Valeria Coluccio, Ilaria Iacobucci, Claudia Venturi, Mario Luppi, Emanuela Ottaviani, Federica Cattina, Robin Foà, MD, Antonella Vitale, Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli

Blood (2012) 120 (21): 284.

https://doi.org/10.1182/blood.V120.21.284.284

Published: 2012

Journal Articles

Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,

Stefano Iacovelli, Maria Rosaria Ricciardi, PhD, Paola Bergamo, Cinzia Rinaldo, PhD, Roberto Licchetta, Antonella Vitale, Anna Testi, MD, Maria Teresa Petrucci, MD, Marina Konopleva, MD, PhD, Michele Milella, MD, Robin Foà, Agostino Tafuri

Blood (2011) 118 (21): 3581.

https://doi.org/10.1182/blood.V118.21.3581.3581

Published: 2011

Journal Articles

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Simona Soverini, Caterina De Benedittis, Alessandra Gnani, Ilaria Iacobucci, PhD, Domenico Russo, Federica Cattina, MD, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Antonella Vitale, Loredana Elia, Robin Foà, Francesca Palandri, Annalisa Lonetti, Maria Teresa Bochicchio, Sandra Durante, Gianantonio Rosti, MD, Michele Baccarani, MD, Giovanni Martinelli

Blood (2011) 118 (21): 3775.

https://doi.org/10.1182/blood.V118.21.3775.3775

Published: 2011

Journal Articles

Alteration of BIRC3 and Multiple Other NF-κB Pathway Genes in Splenic Marginal Zone Lymphoma

Blood (2011) 118 (21): 264.

https://doi.org/10.1182/blood.V118.21.264.264

Published: 2011

Journal Articles

Mutations of NOTCH1 Are An Independent Predictor of Survival in Chronic Lymphocytic Leukemia

Blood (2011) 118 (21): 283.

https://doi.org/10.1182/blood.V118.21.283.283

Published: 2011

Journal Articles

Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY

Blood (2011) 118 (21): 2837.

https://doi.org/10.1182/blood.V118.21.2837.2837

Published: 2011

Journal Articles

Mutations of the SF3B1 splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness

Blood (2011) 118 (21): 464.

https://doi.org/10.1182/blood.V118.21.464.464

Published: 2011

Journal Articles

Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia

Marco Fangazio, Silvia Rasi, Tiziana Vaisitti, Sara Monti, Stefania Cresta, Alessio Bruscaggin, Valeria Spina, Francesco Forconi, Sabina Chiaretti, Anna Guarini, Silvia Deaglio, Robin Foà, Gianluca Gaidano, Davide Rossi

Blood (2011) 118 (21): 466.

https://doi.org/10.1182/blood.V118.21.466.466

Published: 2011

Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

Blood (2011) 118 (21): 475.

https://doi.org/10.1182/blood.V118.21.475.475

Published: 2011

Journal Articles

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Blood (2011) 118 (21): 575.

https://doi.org/10.1182/blood.V118.21.575.575

Published: 2011

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship

Blood (2010) 116 (21): 3601.

https://doi.org/10.1182/blood.V116.21.3601.3601

Published: 2010

NARROW

Single Cell Network Profiling (SCNP) of Early-Stage Chronic Lymphocytic Leukemia (CLL): Association with p53, IGHV Mutational Status and Time to First Treatment (TTFT)

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Targeting Metabolic Pathways for Leukemia Treatment

Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).

Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Alteration of BIRC3 and Multiple Other NF-κB Pathway Genes in Splenic Marginal Zone Lymphoma

Mutations of NOTCH1 Are An Independent Predictor of Survival in Chronic Lymphocytic Leukemia

Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY

Mutations of the SF3B1 splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness

Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only